GET DAILY SIGNALSElectromed (ELMD): The +70% Upside Implied by Current Analyst Targets
Key Takeaways
- The central target of $46 is the arithmetic mean of three verified, current analyst price targets from Lake Street ($47), Freedom Broker ($50), and B. Riley Securities ($40).
- With the stock near $27.06, reaching $46 would require a gain of roughly 70%, a very large move by conventional standards.
- The analyst target range is wide, from $40 to $50, reflecting different assumptions about growth durability and valuation rather than any disagreement on direction.
- Bullish drivers include a debt-free balance sheet, high-70s gross margins, 15 consecutive quarters of revenue and profit growth, and an underpenetrated bronchiectasis market.
- The biggest risks are Electromed's single-product concentration, small-cap trading dynamics, a planned CEO transition in 2027, and the gap between the current price and Street targets.
- For more context on this ticker, explore its Major News, Today's Price Move, Forecast, and Earnings pages.
- You can also explore Trending AI Robots to see how AI-driven strategies are tracking this and other names.
Analyst Price Targets and Consensus View
Electromed, Inc. (NYSE American: ELMD), a Minnesota-based medical device company, carries a modest but active sell-side following. Three current analyst price targets form the basis of the central figure used here: Lake Street raised its target to $47 from $36 on August 26, 2026, reiterating a Buy; Freedom Broker set a $50 target on the same date; and B. Riley Securities moved to $40 from $38 on May 13, 2026, also with a Buy rating. Averaging these three values yields $45.67, rounded to a clean $46.
The range spans $40 to $50, and all three firms carry constructive ratings. The reasoning is consistent: Electromed's direct-to-patient model, expanding payer coverage, and a large, under-treated bronchiectasis population support durable double-digit growth. The spread between the lowest and highest targets is less about disagreement over the business and more about the valuation multiple each firm assigns to a fast-growing, single-product small-cap. It is important to note that $46 is a calculated average, not an official published consensus. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Current Market Position and Path Toward the Target
At its latest verified close near $27.06, ELMD trades roughly 70% below the central $46 target. That gap qualifies as a very large required move, and it reflects a notable disconnect between the stock's recent trading range — the 52-week span is $23.01 to $47.40 — and where analysts see fair value.
The fundamental backdrop supports the higher figures. For fiscal 2026, Electromed reported record net revenue of $73.8 million, up 15.3% year over year, net income of $11.3 million ($1.30 per diluted share), and an operating margin of 18.8%, up more than 370 basis points. Gross margin sits in the high-70s, and the company holds about $20.5 million in cash with no debt. Management guided to double-digit revenue growth and continued operating leverage for fiscal 2027.
What Could Support a Move Toward the Target
- Large, underpenetrated market: Management estimates about 800,000 diagnosed U.S. bronchiectasis patients could benefit from its SmartVest therapy, with only a small share currently using high-frequency chest wall oscillation (HFCWO).
- Reimbursement momentum: The company reported 87% of covered lives under contract, having added 40 new payer contracts and more than 6 million covered lives in fiscal 2026.
- Operational leverage: Operating income rose 43.7% in fiscal 2026, and productivity per sales representative exceeded targets, supporting margin expansion.
- Financial strength: A debt-free balance sheet and positive cash flow give flexibility for sales-force expansion and product development.
What Could Prevent the Target From Being Reached
- Single-product concentration: Essentially all revenue depends on the SmartVest airway clearance system, heightening execution and clinical-adoption risk.
- Small-cap volatility: With a market capitalization near $224 million, the stock can swing sharply on modest news, and it has traded well below prior highs.
- Leadership transition: The chief executive announced plans to retire effective April 2027, introducing succession uncertainty into the growth story.
- Valuation debate: At roughly 20 to 21 times trailing earnings, the market is pricing growth conservatively relative to analyst targets, and a multiple re-rating is not assured.
Technical Levels and Market Structure
The 52-week range of $23.01 to $47.40 defines the key technical boundaries. The lower end near $23 has acted as support, while the $47 area — just below the $47.40 prior high — represents a major resistance zone that coincides with Lake Street's target. The central $46 target sits essentially at that resistance level, meaning a move to $46 would require the stock to reclaim and hold territory it surrendered after reaching its 2026 peak. A psychological threshold at $30 is the first meaningful level overhead on any recovery path. From what I see, reviewing patterns with Tickeron’s AI Real Time Patterns helps clarify these boundaries.
Time Horizon and What Investors Should Monitor
Analyst price targets typically reflect a roughly 12-month horizon, though no firm published a precise time frame here. The most important near-term catalyst is Electromed's next earnings report and updated guidance, where investors will look for continued double-digit growth and confirmation of operating leverage. Other items to watch include analyst revisions following results, sales-representative productivity, payer-contract additions, any update on the CEO succession, and broader small-cap and healthcare sector sentiment.
Final Assessment
The central $46 target — an average of three current analyst targets ranging from $40 to $50 — implies a roughly 70% advance from the latest price near $27, a very large move that hinges on the market assigning a higher valuation to a business already delivering double-digit growth, high margins, and no debt. The supports are tangible: an underpenetrated bronchiectasis market, expanding reimbursement, and consistent operational leverage. The obstacles are equally real: single-product risk, small-cap volatility, a looming CEO transition, and the wide gap between the stock's recent trading and analyst fair-value estimates. Whether the shares close that gap depends on sustained execution and a re-rating by investors, neither of which is guaranteed. I’m watching this closely as the next earnings release approaches.
Exploring AI Daily Buy/Sell Signals for Stocks Like ELMD
In my own workflow, Tickeron’s AI Daily Buy/Sell Signals have become a useful way to stay on top of names like this. The tool applies artificial intelligence to monitor thousands of stocks and ETFs, producing Buy, Sell, or Hold signals based on shifting market conditions and technical behavior. For a volatile small-cap such as Electromed, this automated approach can surface opportunities and highlight trend changes more efficiently than manual review alone. It fits naturally into a broader research process without replacing fundamental analysis.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
ELMD's Indicator enters downward trend
The Aroon Indicator for ELMD entered a downward trend on November 04, 2026. Tickeron's A.I.dvisor identified a pattern where the AroonDown red line was above 70 while the AroonUp green line was below 30 for three straight days. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options. A.I.dvisor looked at 172 similar instances where the Aroon Indicator formed such a pattern. In 123 of the 172 cases the stock moved lower. This puts the odds of a downward move at 72%.
Technical Analysis (Indicators)
Bearish Trend Analysis
ELMD moved below its 50-day moving average on November 05, 2026 date and that indicates a change from an upward trend to a downward trend.
The 50-day moving average for ELMD moved below the 200-day moving average on October 16, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ELMD declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 66%.
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where ELMD's RSI Indicator exited the oversold zone, 19 of 28 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 68%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 51 of 72 cases where ELMD's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 71%.
The Momentum Indicator moved above the 0 level on November 06, 2026. You may want to consider a long position or call options on ELMD as a result. In 89 of 118 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 75%.
Following a +3.83% 3-day Advance, the price is estimated to grow further. Considering data from situations where ELMD advanced for three days, in 184 of 261 cases, the price rose further within the following month. The odds of a continued upward trend are 70%.
ELMD may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron SMR rating for this company is 42 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Profit vs. Risk Rating rating for this company is 52 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock slightly better than average.
The Tickeron Price Growth Rating for this company is 61 (best 1 - 100 worst), indicating fairly steady price growth. ELMD’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 80 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 100 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.211) is normal, around the industry mean (4.142). P/E Ratio (19.832) is within average values for comparable stocks, (3.291). ELMD's Projected Growth (PEG Ratio) (103.010) is very high in comparison to the industry average of (11.253). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (3.080) is also within normal values, averaging (40.124).
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of airway clearance products
Industry MedicalNursingServices
Advertisement